Pulmonary Rehabilitation in patients with Interstitial Lung Disease: The effects of a 12-week programme

Sciriha, Anabel; Lungaro-Mifsud, Stephen; Fsadni, Peter; Scerri, Josianne; Montefort, Stephen

doi:10.1016/j.rmed.2018.11.007

Cited by 27 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study tested the 6MWD as the primary outcome and quality-of-life changes as secondary outcomes between active and inactive patient groups after a 12-week pulmonary rehabilitation programme (NCT03542318). The active group presented significantly better functional and health status after pulmonary rehabilitation [162]. Another ongoing study is testing the same outcomes comparing nintedanib versus nintedanib plus pulmonary rehabilitation patient groups (NCT03717012).…”

Section: Pulmonary Rehabilitationmentioning

confidence: 98%

The therapy of idiopathic pulmonary fibrosis: what is next?

et al. 2019

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death. The pathophysiological understanding, clinical diagnostics and therapy of IPF have significantly evolved in recent years. While the recent introduction of the two antifibrotic drugs pirfenidone and nintedanib led to a significant reduction in lung function decline, there is still no cure for IPF; thus, new therapeutic approaches are needed. Currently, several clinical phase I–III trials are focusing on novel therapeutic targets. Furthermore, new approaches in nonpharmacological treatments in palliative care, pulmonary rehabilitation, lung transplantation, management of comorbidities and acute exacerbations aim to improve symptom control and quality of life. Here we summarise new therapeutic attempts and potential future approaches to treat this devastating disease.

show abstract

Section: Pulmonary Rehabilitationmentioning

confidence: 98%

The therapy of idiopathic pulmonary fibrosis: what is next?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…From these, unstable cardiovascular disease [198,199,202,203,208,209] ( n = 6; 37.5%) was the most reported criterion, followed by contraindications to exercise training and/or testing (e.g., unstable angina, recent myocardial infarction or cerebrovascular accident) [201,204,207] ( n = 3; 18.8%). Four (25.0%) studies [185,197,205,206] did not report any information about exclusion criteria.…”

Section: Resultsmentioning

confidence: 99%

“…In general, 22.8% of the studies [23,48,50,55,63,67,69,73,77,78,79,80,83,84,86,88,91,95,97,110,111,115,122,126,127,132,142,149,150,155,161,165,175,185,187,189,190,193,197,205,206] did not report information about the eligibility criteria, 18.3% of the studies [33,42,54,65,66,72,82,96,98,99,101,108,116,117,118,119,128,137,141,143,145,146,180,182,194,195,200,201,202,203,207,208,…”

Section: Resultsmentioning

confidence: 99%

Exercise Training in Patients with Chronic Respiratory Diseases: Are Cardiovascular Comorbidities and Outcomes Taken into Account?—A Systematic Review

Machado

Quadflieg

Oliveira

et al. 2019

JCM

View full text Add to dashboard Cite

Patients with chronic obstructive pulmonary disease (COPD), asthma and interstitial lung diseases (ILD) frequently suffer from cardiovascular comorbidities (CVC). Exercise training is a cornerstone intervention for the management of these conditions, however recommendations on tailoring programmes to patients suffering from respiratory diseases and CVC are scarce. This systematic review aimed to identify the eligibility criteria used to select patients with COPD, asthma or ILD and CVC to exercise programmes; assess the impact of exercise on cardiovascular outcomes; and identify how exercise programmes were tailored to CVC. PubMed, Scopus, Web of Science and Cochrane were searched. Three reviewers extracted the data and two reviewers independently assessed the quality of studies with the Quality Assessment Tool for Quantitative Studies. MetaXL 5.3 was used to calculate the individual and pooled effect sizes (ES). Most studies (58.9%) excluded patients with both stable and unstable CVC. In total, 26/42 studies reported cardiovascular outcomes. Resting heart rate was the most reported outcome measure (n = 13) and a small statistically significant effect (ES = −0.23) of exercise training on resting heart rate of patients with COPD was found. No specific adjustments to exercise prescription were described. Few studies have included patients with CVC. There was a lack of tailoring of exercise programmes and limited effects were found. Future studies should explore the effect of tailored exercise programmes on relevant outcome measures in respiratory patients with CVC.

show abstract

“…It is hypothesized that PR can also be used as a treatment method in ILD patients and delay the progression of the disease; however, there are currently no detailed guidelines on the use of PR in ILD patients (Igarashi et al 2018). Several studies have shown that the PR program has several benefits tailored to improving the prognosis of ILD patients (Sciriha et al 2019;Wallaert et al 2019;Yuen et al 2019). Few studies focus on the long-term effects of home-based PR programs on patients.…”

Section: Discussionmentioning

confidence: 99%

Long-term effects of home-based pulmonary rehabilitation on idiopathic interstitial pneumonia patients

et al. 2021

View full text Add to dashboard Cite

Currently, interstitial lung disease (ILD) has no unified treatment plan. Home-based pulmonary rehabilitation (PR), as a non-pharmacological treatment, is a non-invasive and low-cost option for improving exercise capacity and quality of life. This study explores the impact of home-based PR on lung function, and the quality of life of patients with ILD. In this randomized prospective study, 60 patients with ILD were randomly assigned to the home-based PR intervention and traditional drug treatment groups, and they were followed for 12 months. The outcome measures were the 6-min walk distance (6MWD), exercise-related dyspnea, and St George's Respiratory Questionnaire score (SGRQ). It found that the 6MWD results were significantly improved from 348.5 ± 106.1 m at baseline to 403.6 ± 100.3 m on the completion of PR and 443.8 ± 96.5 at 1-year follow-up (P = 0.001). Compared with the control group, the home-based PR group had slightly improved pulmonary function. Furthermore, the severity of dyspnea evaluated with mMRC in the home-based PR group improved from 2.9 ± 1.1 at baseline to 2.2 ± 0.9 after the home-based PR program, and this improvement persisted after 12 months (P = 0.001). Additionally, home-based PR for patients with ILD improved the functional pulmonary performance and the SGRQ score results.

show abstract

Pulmonary Rehabilitation in patients with Interstitial Lung Disease: The effects of a 12-week programme

Cited by 27 publications

References 17 publications

The therapy of idiopathic pulmonary fibrosis: what is next?

The therapy of idiopathic pulmonary fibrosis: what is next?

Exercise Training in Patients with Chronic Respiratory Diseases: Are Cardiovascular Comorbidities and Outcomes Taken into Account?—A Systematic Review

Long-term effects of home-based pulmonary rehabilitation on idiopathic interstitial pneumonia patients

Contact Info

Product

Resources

About